Locally Advanced or Metastatic Urothelial Carcinoma (UC) Approved for Marketing Phase Trials for Enfortumab vedotin (DB13007)

IndicationStatusPhase
DBCOND0123651 (Locally Advanced or Metastatic Urothelial Carcinoma (UC))Approved for MarketingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04136808An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma